Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
William L. Dahut(National Cancer Institute), William D. Figg(National Cancer Institute), Allyson L. Parr, Jürgen Venitz(National Cancer Institute), Diana Nguyen, Seth M. Steinberg(National Institutes of Health), Sherry Yang, Alex Sparreboom(The Ohio State University), James L. Gulley(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), Debbie McNally, Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Herbert L. Kotz, Elise C. Kohn(National Cancer Institute)
Cited by 155
Related Papers
Cremophor EL
|European Journal of Cancer|2001|1.6k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|973
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766